BiotechTubeBiotechTube
Home/Entrada Therapeutics/Dipal D. Patel
DD

Dipal D. Patel

Chief Executive Officer

Entrada Therapeutics

Therapeutic Areas

Neuromuscular DisordersMetabolic DiseasesGenetic Disorders

Entrada Therapeutics Pipeline

DrugIndicationPhase
ENTR-601-44Duchenne Muscular Dystrophy (exon 44 skipping)Phase 1/2
ENTR-601-45Duchenne Muscular Dystrophy (exon 45 skipping)Phase 1
ENTR-601-51Duchenne Muscular Dystrophy (exon 51 skipping)Phase 1
ENTR-701Myotonic Dystrophy Type 1 (DM1)Preclinical
ENTR-501Undisclosed Lysosomal Storage DisorderPreclinical

Leadership Team at Entrada Therapeutics

KA
Katherine A. High
President, Head of Research and Development
PS
Peter S. Svennilson
Chairman of the Board
VM
Victor M. Moyo
Chief Business Officer and General Counsel
SL
Scott L. Burrows
Chief Financial Officer
JM
Joe McCracken
Chief Business Officer
MD
Michael D. Ehlers
Board Member
JT
John T. Greene
Board Member
ST
Samantha Truex
Board Member
NB
Nessan Bermingham
Board Observer
View full Entrada Therapeutics profile